Psomagen Becomes the First US-Based Alithea Genomics Certified Service Provider

Rockville, Md, — November 10, 2026 — Psomagen is now a Certified Service Provider (CSP) for Alithea Genomics. We earned CSP status on September 2, 2026, becoming the first U.S.-based CSP for Alithea Genomics.

Who is Alithea Genomics?

Alithea Genomics is a Swiss company that develops high-throughput RNA sequencing technologies. It was founded in May 2020 at EPFL in Lausanne, Switzerland, and its story began with BRB-seq, a bulk RNA barcoding and sequencing method. Its two main technologies, MERCURIUS™ BRB-seq and DRUG-seq, let labs run RNA-seq on hundreds of samples at once, at a fraction of the usual cost and time.

What are BRB-seq and DRUG-seq?

Both methods add a barcode to each sample at the start of library prep. This lets up to 384 samples be pooled and run as one library, which lowers cost and hands-on time.

• MERCURIUS™ BRB-seq is a high-throughput, cost-effective solution that transforms purified RNA from 96- or 384-well plates into 3′ mRNA-seq libraries, pooling up to 384 samples in a single tube. Ideal for large cohorts, time-course experiments, and gene expression studies across multiple species, BRB-seq can detect approximately 13,000 genes per sample at just 1.5 million reads.
• MERCURIUS™ DRUG-seq enables high-throughput gene expression profiling directly from cells, eliminating the need for RNA extraction. Customers simply send frozen cells in 96- or 384-well plates. Ideal for drug screening, toxicology, and mechanism-of-action (MoA) studies, DRUG-seq is compatible with a wide range of cell lines and primary cells, detecting over 13,000 genes per sample at just 1 million reads.

Both services join Psomagen's existing mRNA sequencing portfolio.

Ready to plan a BRB-seq or DRUG-seq project? Contact our team for a quote or to talk through your study design.

About Psomagen

Psomagen, formerly Macrogen, is a Contract Research Services (CRO) provider celebrating its 22nd year anniversary in 2026 – over this time it has offered genomic, transcriptomic, and proteomic analysis to research programs and operations throughout North America, serving academic, pharma, biotech, government and industry. Its US-based, CAP and CLIA certified laboratories are located in Rockville, MD and Boston, MA and provide genomics, transcriptomics and proteomics technologies such as short and long-read next-generation sequencing (NGS), Sanger (CE) sequencing, microarray, single-cell omics, metagenomics and microbiome, spatial biology, bioinformatics and biomarker discovery. Psomagen utilizes state-of-the-art technology from partners such as Illumina, 10X Genomics, and Olink among others, providing services including nucleic acid or protein extraction, sample quality control, assay preparation, analysis and interpretation.

Sources

• Alithea Genomics: MERCURIUS™ BRB-seq service
• Alithea Genomics: MERCURIUS™ DRUG-seq service
• Alithea Genomics: CHF 6.9M seed round release